Stayble accelerates partnering process with the support of advisors
Stayble Therapeutics AB ("Stayble" or "the Company") today announces the intensification of its partnering activities with the company’s drug candidate STA363 in collaboration with a renowned transaction advisor. The company’s objective for the STA363 pain project is to identify a partner with the appropriate expertise and financial resources to advance the clinical development of STA363 towards commercialization.
According to the board and management, interest from potential stakeholders has significantly increased since Stayble presented the positive results from the company’s Phase 1b study. Stayble is now focused on accelerating and optimizing the process of finding the right partner for STA363, aiming to enhance the value of a potential deal. The transaction advisor is engaging with pharmaceutical companies and venture capital firms to maximize the continued development of STA363.
Andreas Gerward, CEO of Stayble Therapeutics, comments:
“We have ongoing promising discussions and have an excellent collaboration with the transaction advisor. With their specialized knowledge and network, they are the right support for us in finding a partner. Their experience, expertise, and network provide us with great opportunities to initiate a partnership with the right collaborator who can manage and further develop STA363, thereby increasing shareholder value. We look forward to continuing to update the market on the progress of this process.”
For more information
Andreas Gerward, CEO of Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for lumbar disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company has successfully completed a phase 1b study for the treatment of herniated discs.
The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.